{"id":1463,"date":"2025-10-01T08:00:43","date_gmt":"2025-10-01T07:00:43","guid":{"rendered":"https:\/\/www.competitionlawyers.co.uk\/blog\/?p=1463"},"modified":"2025-08-07T08:58:03","modified_gmt":"2025-08-07T07:58:03","slug":"vifor-pharma-investigation-cma-focus-on-intravenous-iron-treatments","status":"publish","type":"post","link":"https:\/\/www.competitionlawyers.co.uk\/blog\/vifor-pharma-investigation-cma-focus-on-intravenous-iron-treatments","title":{"rendered":"Vifor Pharma Investigation: CMA Focus On Intravenous Iron Treatments"},"content":{"rendered":"

The Competition and Markets Authority (CMA) in the UK has been investigating Vifor Pharma, a global pharmaceutical company, reportedly for suspected anti-competitive conduct related to intravenous iron treatments.<\/p>\n

The pharmaceutical industry plays a critical role in ensuring patients receive safe and effective treatments, but when companies engage in anti-competitive behaviour<\/strong><\/a>, it can harm patients, healthcare systems, and fair market competition.<\/p>\n

This investigation, reportedly launched on 31 January 2024, centres on concerns that Vifor Pharma may have disparaged a rival product, Monofer, to promote its own product, Ferinject, potentially misleading healthcare professionals and affecting patient care. The CMA is committed to holding corporations accountable for such practices and ensuring justice for those impacted.<\/p>\n

<\/p>\n

The CMA\u2019s Investigation into Vifor Pharma Intravenous Iron Treatments<\/strong><\/h3>\n

The CMA\u2019s probe<\/strong><\/a> focuses on whether Vifor Pharma, a leading supplier of intravenous iron treatments, abused a dominant position in the UK market by making misleading claims about the safety and effectiveness of Monofer, a competing product supplied by Pharmacosmos. Both Ferinject (Vifor\u2019s product) and Monofer are critical intravenous iron treatments used to address iron deficiency anaemia, a condition affecting approximately four million people in the UK, particularly those for whom oral iron supplements are unsuitable, such as patients undergoing major surgery or with long-term health conditions.<\/p>\n

The CMA suspects that Vifor Pharma\u2019s claims were designed to hinder competition by creating doubts about Monofer\u2019s safety, thereby promoting Ferinject. Such actions could restrict patient access to alternative treatments and place an undue financial burden on the National Health Service (NHS).<\/p>\n

On 10 December 2024, the CMA announced its intention to accept commitments from Vifor Pharma, including a \u00a323 million ex gratia payment to the NHS and a multi-channel communication campaign to correct misleading information disseminated to healthcare professionals. These commitments aim to address the CMA\u2019s concerns without proceeding to a formal ruling on whether Vifor broke competition law.<\/p>\n

Impact on Patients and the NHS<\/strong><\/h3>\n

The implications of Vifor Pharma\u2019s alleged conduct could be significant for both patients and the NHS. Iron deficiency anaemia can cause severe symptoms, including fatigue, heart palpitations, and dizziness, making access to effective intravenous iron treatments essential. Misleading claims about a competitor\u2019s product could limit doctors\u2019 and patients\u2019 treatment options, potentially compromising patient care. Furthermore, by stifling competition, Vifor\u2019s actions may have led to higher costs for the NHS, as reduced competition often results in inflated prices for essential medications.<\/p>\n

The proposed \u00a323 million payment to the NHS, if accepted, could help alleviate some of the financial strain caused by these practices. Additionally, Vifor\u2019s commitment to a communication campaign to rectify misleading statements about Monofer and Ferinject underscores the importance of accurate information in healthcare decision-making. However, these remedies may not fully address the harm caused to patients and the market, which is why legal action, such as that pursued by The Competition Lawyers, is crucial to ensure accountability and compensation.<\/p>\n

Importance of Investigations<\/strong><\/h3>\n

Companies like Vifor Pharma must be held accountable for actions that undermine fair competition and harm consumers. Robust legal frameworks must protect patients and healthcare systems from such practices.<\/p>\n

The Vifor Pharma investigation highlights the critical need for accountability in the pharmaceutical industry, particularly when it comes to essential treatments like intravenous iron treatments.<\/p>\n","protected":false},"excerpt":{"rendered":"

The Competition and Markets Authority (CMA) in the UK has been investigating Vifor Pharma, a global pharmaceutical company, reportedly for suspected anti-competitive conduct related to intravenous iron treatments. The pharmaceutical industry plays a critical role in ensuring patients receive safe and effective treatments, but when companies engage in anti-competitive behaviour, it can harm patients, healthcare … Continue reading Vifor Pharma Investigation: CMA Focus On Intravenous Iron Treatments<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":1464,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[37,59,58,13,10,1,40],"tags":[29,2,15,61,54,45,35],"class_list":["post-1463","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-compensation-claims","category-consumer-law","category-healthcare","category-industry","category-investigations","category-latest","category-market-dominance-abuse","tag-advertising","tag-cma","tag-competition-law","tag-consumer-law","tag-healthcare","tag-investigations","tag-market-abuse"],"yoast_head":"\nVifor Pharma Investigation: CMA Focus On Intravenous Iron Treatments - Competition Lawyers<\/title>\n<meta name=\"description\" content=\"CMA in the UK has been investigating Vifor Pharma for suspected anti-competitive conduct related to intravenous iron treatments.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.competitionlawyers.co.uk\/blog\/vifor-pharma-investigation-cma-focus-on-intravenous-iron-treatments\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vifor Pharma Investigation: CMA Focus On Intravenous Iron Treatments - Competition Lawyers\" \/>\n<meta property=\"og:description\" content=\"CMA in the UK has been investigating Vifor Pharma for suspected anti-competitive conduct related to intravenous iron treatments.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.competitionlawyers.co.uk\/blog\/vifor-pharma-investigation-cma-focus-on-intravenous-iron-treatments\" \/>\n<meta property=\"og:site_name\" content=\"Competition Lawyers\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-01T07:00:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/i0.wp.com\/www.competitionlawyers.co.uk\/blog\/wp-content\/uploads\/2025\/08\/ALSO-CEL-DBL-GAL-GF-SIL-MED-SEOSDB-2023-2-Desk-Computer-Typing-10.jpg?fit=1920%2C1280&ssl=1\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1280\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Author\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@Matt\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Author\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\\\/vifor-pharma-investigation-cma-focus-on-intravenous-iron-treatments#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\\\/vifor-pharma-investigation-cma-focus-on-intravenous-iron-treatments\"},\"author\":{\"name\":\"Author\",\"@id\":\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\\\/#\\\/schema\\\/person\\\/32c18f906b91fed8634e71af54b2a301\"},\"headline\":\"Vifor Pharma Investigation: CMA Focus On Intravenous Iron Treatments\",\"datePublished\":\"2025-10-01T07:00:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\\\/vifor-pharma-investigation-cma-focus-on-intravenous-iron-treatments\"},\"wordCount\":545,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\\\/vifor-pharma-investigation-cma-focus-on-intravenous-iron-treatments#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/i0.wp.com\\\/www.competitionlawyers.co.uk\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/ALSO-CEL-DBL-GAL-GF-SIL-MED-SEOSDB-2023-2-Desk-Computer-Typing-10.jpg?fit=1920%2C1280&ssl=1\",\"keywords\":[\"advertising\",\"cma\",\"competition law\",\"consumer law\",\"healthcare\",\"investigations\",\"market abuse\"],\"articleSection\":[\"Compensation Claims\",\"Consumer Law\",\"Healthcare\",\"Industry\",\"Investigations\",\"Latest\",\"Market Dominance Abuse\"],\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\\\/vifor-pharma-investigation-cma-focus-on-intravenous-iron-treatments#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\\\/vifor-pharma-investigation-cma-focus-on-intravenous-iron-treatments\",\"url\":\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\\\/vifor-pharma-investigation-cma-focus-on-intravenous-iron-treatments\",\"name\":\"Vifor Pharma Investigation: CMA Focus On Intravenous Iron Treatments - Competition Lawyers\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\\\/vifor-pharma-investigation-cma-focus-on-intravenous-iron-treatments#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\\\/vifor-pharma-investigation-cma-focus-on-intravenous-iron-treatments#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/i0.wp.com\\\/www.competitionlawyers.co.uk\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/ALSO-CEL-DBL-GAL-GF-SIL-MED-SEOSDB-2023-2-Desk-Computer-Typing-10.jpg?fit=1920%2C1280&ssl=1\",\"datePublished\":\"2025-10-01T07:00:43+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\\\/#\\\/schema\\\/person\\\/32c18f906b91fed8634e71af54b2a301\"},\"description\":\"CMA in the UK has been investigating Vifor Pharma for suspected anti-competitive conduct related to intravenous iron treatments.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\\\/vifor-pharma-investigation-cma-focus-on-intravenous-iron-treatments#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\\\/vifor-pharma-investigation-cma-focus-on-intravenous-iron-treatments\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\\\/vifor-pharma-investigation-cma-focus-on-intravenous-iron-treatments#primaryimage\",\"url\":\"https:\\\/\\\/i0.wp.com\\\/www.competitionlawyers.co.uk\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/ALSO-CEL-DBL-GAL-GF-SIL-MED-SEOSDB-2023-2-Desk-Computer-Typing-10.jpg?fit=1920%2C1280&ssl=1\",\"contentUrl\":\"https:\\\/\\\/i0.wp.com\\\/www.competitionlawyers.co.uk\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/ALSO-CEL-DBL-GAL-GF-SIL-MED-SEOSDB-2023-2-Desk-Computer-Typing-10.jpg?fit=1920%2C1280&ssl=1\",\"width\":1920,\"height\":1280,\"caption\":\"intravenous iron treatments\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\\\/vifor-pharma-investigation-cma-focus-on-intravenous-iron-treatments#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vifor Pharma Investigation: CMA Focus On Intravenous Iron Treatments\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\\\/#website\",\"url\":\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\\\/\",\"name\":\"Competition Lawyers\",\"description\":\"Latest Legal News, Cases & Articles\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\\\/#\\\/schema\\\/person\\\/32c18f906b91fed8634e71af54b2a301\",\"name\":\"Author\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6df762ce646241b4e07c2c84d0016582f85c0b3c6f2ce06d0eb5d9aed612cc4e?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6df762ce646241b4e07c2c84d0016582f85c0b3c6f2ce06d0eb5d9aed612cc4e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6df762ce646241b4e07c2c84d0016582f85c0b3c6f2ce06d0eb5d9aed612cc4e?s=96&d=mm&r=g\",\"caption\":\"Author\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/Matt\"],\"url\":\"https:\\\/\\\/www.competitionlawyers.co.uk\\\/blog\\\/author\\\/matt\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Vifor Pharma Investigation: CMA Focus On Intravenous Iron Treatments - Competition Lawyers","description":"CMA in the UK has been investigating Vifor Pharma for suspected anti-competitive conduct related to intravenous iron treatments.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.competitionlawyers.co.uk\/blog\/vifor-pharma-investigation-cma-focus-on-intravenous-iron-treatments","og_locale":"en_GB","og_type":"article","og_title":"Vifor Pharma Investigation: CMA Focus On Intravenous Iron Treatments - Competition Lawyers","og_description":"CMA in the UK has been investigating Vifor Pharma for suspected anti-competitive conduct related to intravenous iron treatments.","og_url":"https:\/\/www.competitionlawyers.co.uk\/blog\/vifor-pharma-investigation-cma-focus-on-intravenous-iron-treatments","og_site_name":"Competition Lawyers","article_published_time":"2025-10-01T07:00:43+00:00","og_image":[{"width":1920,"height":1280,"url":"https:\/\/i0.wp.com\/www.competitionlawyers.co.uk\/blog\/wp-content\/uploads\/2025\/08\/ALSO-CEL-DBL-GAL-GF-SIL-MED-SEOSDB-2023-2-Desk-Computer-Typing-10.jpg?fit=1920%2C1280&ssl=1","type":"image\/jpeg"}],"author":"Author","twitter_card":"summary_large_image","twitter_creator":"@Matt","twitter_misc":{"Written by":"Author","Estimated reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.competitionlawyers.co.uk\/blog\/vifor-pharma-investigation-cma-focus-on-intravenous-iron-treatments#article","isPartOf":{"@id":"https:\/\/www.competitionlawyers.co.uk\/blog\/vifor-pharma-investigation-cma-focus-on-intravenous-iron-treatments"},"author":{"name":"Author","@id":"https:\/\/www.competitionlawyers.co.uk\/blog\/#\/schema\/person\/32c18f906b91fed8634e71af54b2a301"},"headline":"Vifor Pharma Investigation: CMA Focus On Intravenous Iron Treatments","datePublished":"2025-10-01T07:00:43+00:00","mainEntityOfPage":{"@id":"https:\/\/www.competitionlawyers.co.uk\/blog\/vifor-pharma-investigation-cma-focus-on-intravenous-iron-treatments"},"wordCount":545,"commentCount":0,"image":{"@id":"https:\/\/www.competitionlawyers.co.uk\/blog\/vifor-pharma-investigation-cma-focus-on-intravenous-iron-treatments#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/www.competitionlawyers.co.uk\/blog\/wp-content\/uploads\/2025\/08\/ALSO-CEL-DBL-GAL-GF-SIL-MED-SEOSDB-2023-2-Desk-Computer-Typing-10.jpg?fit=1920%2C1280&ssl=1","keywords":["advertising","cma","competition law","consumer law","healthcare","investigations","market abuse"],"articleSection":["Compensation Claims","Consumer Law","Healthcare","Industry","Investigations","Latest","Market Dominance Abuse"],"inLanguage":"en-GB","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.competitionlawyers.co.uk\/blog\/vifor-pharma-investigation-cma-focus-on-intravenous-iron-treatments#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.competitionlawyers.co.uk\/blog\/vifor-pharma-investigation-cma-focus-on-intravenous-iron-treatments","url":"https:\/\/www.competitionlawyers.co.uk\/blog\/vifor-pharma-investigation-cma-focus-on-intravenous-iron-treatments","name":"Vifor Pharma Investigation: CMA Focus On Intravenous Iron Treatments - Competition Lawyers","isPartOf":{"@id":"https:\/\/www.competitionlawyers.co.uk\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.competitionlawyers.co.uk\/blog\/vifor-pharma-investigation-cma-focus-on-intravenous-iron-treatments#primaryimage"},"image":{"@id":"https:\/\/www.competitionlawyers.co.uk\/blog\/vifor-pharma-investigation-cma-focus-on-intravenous-iron-treatments#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/www.competitionlawyers.co.uk\/blog\/wp-content\/uploads\/2025\/08\/ALSO-CEL-DBL-GAL-GF-SIL-MED-SEOSDB-2023-2-Desk-Computer-Typing-10.jpg?fit=1920%2C1280&ssl=1","datePublished":"2025-10-01T07:00:43+00:00","author":{"@id":"https:\/\/www.competitionlawyers.co.uk\/blog\/#\/schema\/person\/32c18f906b91fed8634e71af54b2a301"},"description":"CMA in the UK has been investigating Vifor Pharma for suspected anti-competitive conduct related to intravenous iron treatments.","breadcrumb":{"@id":"https:\/\/www.competitionlawyers.co.uk\/blog\/vifor-pharma-investigation-cma-focus-on-intravenous-iron-treatments#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.competitionlawyers.co.uk\/blog\/vifor-pharma-investigation-cma-focus-on-intravenous-iron-treatments"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/www.competitionlawyers.co.uk\/blog\/vifor-pharma-investigation-cma-focus-on-intravenous-iron-treatments#primaryimage","url":"https:\/\/i0.wp.com\/www.competitionlawyers.co.uk\/blog\/wp-content\/uploads\/2025\/08\/ALSO-CEL-DBL-GAL-GF-SIL-MED-SEOSDB-2023-2-Desk-Computer-Typing-10.jpg?fit=1920%2C1280&ssl=1","contentUrl":"https:\/\/i0.wp.com\/www.competitionlawyers.co.uk\/blog\/wp-content\/uploads\/2025\/08\/ALSO-CEL-DBL-GAL-GF-SIL-MED-SEOSDB-2023-2-Desk-Computer-Typing-10.jpg?fit=1920%2C1280&ssl=1","width":1920,"height":1280,"caption":"intravenous iron treatments"},{"@type":"BreadcrumbList","@id":"https:\/\/www.competitionlawyers.co.uk\/blog\/vifor-pharma-investigation-cma-focus-on-intravenous-iron-treatments#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.competitionlawyers.co.uk\/blog"},{"@type":"ListItem","position":2,"name":"Vifor Pharma Investigation: CMA Focus On Intravenous Iron Treatments"}]},{"@type":"WebSite","@id":"https:\/\/www.competitionlawyers.co.uk\/blog\/#website","url":"https:\/\/www.competitionlawyers.co.uk\/blog\/","name":"Competition Lawyers","description":"Latest Legal News, Cases & Articles","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.competitionlawyers.co.uk\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Person","@id":"https:\/\/www.competitionlawyers.co.uk\/blog\/#\/schema\/person\/32c18f906b91fed8634e71af54b2a301","name":"Author","image":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/secure.gravatar.com\/avatar\/6df762ce646241b4e07c2c84d0016582f85c0b3c6f2ce06d0eb5d9aed612cc4e?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/6df762ce646241b4e07c2c84d0016582f85c0b3c6f2ce06d0eb5d9aed612cc4e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/6df762ce646241b4e07c2c84d0016582f85c0b3c6f2ce06d0eb5d9aed612cc4e?s=96&d=mm&r=g","caption":"Author"},"sameAs":["https:\/\/x.com\/Matt"],"url":"https:\/\/www.competitionlawyers.co.uk\/blog\/author\/matt"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/www.competitionlawyers.co.uk\/blog\/wp-content\/uploads\/2025\/08\/ALSO-CEL-DBL-GAL-GF-SIL-MED-SEOSDB-2023-2-Desk-Computer-Typing-10.jpg?fit=1920%2C1280&ssl=1","jetpack-related-posts":[],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.competitionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/posts\/1463","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.competitionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.competitionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.competitionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.competitionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/comments?post=1463"}],"version-history":[{"count":2,"href":"https:\/\/www.competitionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/posts\/1463\/revisions"}],"predecessor-version":[{"id":1478,"href":"https:\/\/www.competitionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/posts\/1463\/revisions\/1478"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.competitionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/media\/1464"}],"wp:attachment":[{"href":"https:\/\/www.competitionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/media?parent=1463"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.competitionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/categories?post=1463"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.competitionlawyers.co.uk\/blog\/wp-json\/wp\/v2\/tags?post=1463"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}